Advise your patients to always keep HUMIRA cold:¹

• Keeping HUMIRA between 2°–8°C to ensure that the medication remains effective.
• Keep HUMIRA in a clean and hygienic spot in the refrigerator to avoid contamination. Do not freeze HUMIRA.
• Keep in its original packaging.
• Keep HUMIRA out of reach from children, even in the fridge.
• For ease of use at home, a single HUMIRA Pen or Syringe can be stored at room temperature (below 25°C) for a maximum period of 14 days.
• Protect from light.
• Once HUMIRA has reached room temperature, it must be used or discarded within 14 days. (This is the case, even if they return it to the fridge within those 14 days.)
• Keep the medicine at the right temperature when they travel. This is important when travelling by car, bus, train, plane or any other form of transport. This includes on the way home from the pharmacy.

For free travel solutions for your patients on HUMIRA, you may refer them to the AbbVie Care^® Patient Support Program available through HUMIRA Destination Pharmacy in PlusOne.

Click the guide below and learn how to get started.

For more information, please contact our Customer Support Team on 1300 125 343.

Please review Product Information before prescribing. Product Information is available on request from AbbVie Pty Ltd by calling 1800 043 460 or at www.medicines.org.au.

MINIMUM PRODUCT INFORMATION: HUMIRA (adalimumab). INDICATIONS: Rheumatoid Arthritis (RA): Reducing signs & symptoms, and inhibiting the progression of structural damage, in adults with moderate to severely active RA; including patients with recently diagnosed moderate to severely active disease who have not received methotrexate. Humira can be used alone or in combination with methotrexate. Juvenile Idiopathic Arthritis: Polyarticular Juvenile Idiopathic Arthritis (PJIA) Humira in combination with methotrexate is indicated for reducing the signs and symptoms of moderately to severely active PJIA in patients 2 years of age and older with an inadequate response to one or more disease modifying anti-rheumatic drugs (DMARDs). Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Enthesitis-Related Arthritis (ERA) Treatment of ERA in children, with an inadequate response, or intolerance to, conventional therapy.Psoriatic Arthritis (PsA): Treatment of signs and symptoms, and inhibiting the progression of structural damage, of moderate to severely active PsA in adult patients with inadequate response to DMARDS. Ankylosing Spondylitis (AS): Reducing signs and symptoms in patients with active AS. Crohn’s Disease (CD) in Adults and Children (≥ 6 years): Treatment of moderate to severe CD, to reduce the signs and symptoms of the disease and to induce and maintain clinical remission in patients with; inadequate response to conventional therapies or, who have lost response to or are intolerant of, infliximab. Ulcerative colitis (UC): Treatment of moderate to severe UC in adult patients with intolerance, medical contraindication, or inadequate response to conventional therapy. Patients should show a clinical response within 8 weeks of treatment to continue treatment beyond that time. Psoriasis in Adults and Children (≥ 4 years): Treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Treatment of severe chronic plaque psoriasis in children and adolescent patients with an inadequate response to, or are inappropriate candidates for, topical therapy and phototherapy. Hidradenitis Suppurativa (HS) in Adults and Adolescents (≥ 12 years): Treatment of active moderate to severe HS (acne inversa) in patients with an inadequate response to conventional systemic HS therapy. Uveitis: Treatment of non-infectious intermediate, posterior and pan-uveitis in adult patients with inadequate response to corticosteroids, those in need of corticosteroid sparing, or in whom corticosteroid treatment is inappropriate. CONTRAINDICATIONS: Severe infections including sepsis, active tuberculosis, opportunistic infections; concurrent anakinra administration; moderate to severe heart failure (NYHA class III/IV); known hypersensitivity to HUMIRA or its excipients.PRECAUTIONS: Infections (bacterial, mycobacterial, invasive fungal e.g, histoplasmosis, viral or other opportunistic); hepatitis B, TB (reactivation, new onset or latent); demyelinating disorders* (central or peripheral; neurologic evaluation required prior to initiation and ongoing for patients with intermediate uveitis); haematologic events; live vaccines; immunosuppression; new or worsening CHF; renal, hepatic impairment; malignancy; hypersensitivity reactions;; autoimmune processes (auto antibodies, lupus-like syndrome), use in psoriasis with phototherapy, concurrent biologic DMARDs or other TNF antagonists; elderly; pregnancy, lactation, surgery. *Refer to Product Information under Neurologic Events. ADVERSE REACTIONS: Respiratory tract infections, leukopaenia, anaemia, lipid increase, headache, abdominal pain, nausea and vomiting, elevated liver enzymes, rash, musculoskeletal pain, injection site reaction are very commonly seen adverse events. Benign neoplasm and skin cancer including basal cell and squamous cell carcinoma were commonly reported. Fatal infections such as TB and invasive opportunistic infections have rarely been reported. For others, see full PI.DOSAGE & ADMINISTRATION: Humira doses are to be administered by subcutaneous injection. Refer to the PI for full dosing instructions. RA, PsA and AS: 40 mg fortnightly as a single dose. PJIA & ERA: Paediatric Patients (≥ 2 years): 10 kg to <15 kg = 10 mg fortnightly; 15 kg to <30 kg = 20 mg fortnightly; ≥ 30 kg = 40 mg fortnightly. CD and UC (Adults): Induction: 160 mg on Day 0 (given in one day or as 80 mg per day for two consecutive days), followed by 80 mg on Day 14. Maintenance: 40 mg starting on Day 28 and continuing fortnightly. pCD: Paediatric Patients (6 to 17 years): < 40 kg – Induction: 80 mg on Day 0, followed by 40 mg on Day 14. Maintenance: 20 mg starting on Day 28 and continuing fortnightly. ≥ 40 kg – Induction: 160 mg on Day 0 (given in one day or as 80 mg per day for two consecutive days), followed by 80 mg on Day 14. Maintenance: 40 mg starting on Day 28 and continuing fortnightly. Psoriasis & Uveitis (Adults): Initial dose of 80 mg, followed by 40 mg fortnightly, starting one week after the initial dose. Paediatric Plaque Psoriasis (4 to 17 years): Doses to be given weekly for the first two doses and fortnightly thereafter. Dose based on bodyweight: ≥ 40 kg = 20 mg; ≥ 40 kg = 40 mg HS (Adults): Induction: 160 mg on Day 0 (given in one day or as 80 mg per day for two consecutive days), followed by 80 mg on Day 14. Maintenance: 40 mg starting on Day 28 and continuing weekly. HS (≥ 12 years, ≥ 30kg): Initial dose of 80 mg, followed by 40 mg fortnightly, starting one week after the initial dose. Version 34a.

References: 1. Humira Approved Product Information

AbbVieR and AbbVie CareR are registered trademarks of AbbVie Inc. and HumiraR is a registered trademark of AbbVie Biotechnology Ltd. AbbVie Pty Ltd, ABN 48 156 384 262, Mascot NSW 2020. Medical information phone: 1800 043 460. www.abbvie.com.au.AU-HUM-190067. Date Prepared September 2019